Cardiovascular Calcification in Patients With End-stage Renal Disease

• Published in: Therapeutic apheresis and dialysis 2005-06, Vol.9 (3), p.208-210
• Main Author: Pečovnik-Balon, Breda
• Format: Article
• Language: English
• Subjects: Calcinosis - etiology; Calcinosis - prevention & control; Cardiovascular calcification; Chronic renal disease; End-stage renal disease; Hemodialysis Solutions - chemistry; Hemodialysis Solutions - therapeutic use; Humans; Kidney Failure, Chronic - complications; Phosphorus; Risk Factors; Sevelamer; Vascular Diseases - etiology; Vascular Diseases - prevention & control
• ISSN: 1744-9979; 1744-9987
• DOI: 10.1111/j.1774-9987.2005.00255.x

:   Vascular calcifications are very frequent extraosseous calcifications in patients with chronic renal disease. They occur in the intima and in the media. They are associated with decreased arterial elasticity and increased mortality. The risk factors are: advanced age, duration of dialysis treatment, diabetes, increased phosphate concentration, the dose of Ca‐containing phosphate binders and inflammation. It is now well established that vascular smooth muscle cells actively take up phosphate to form bioapatite. This process is associated with a phenotypic transformation of vascular smooth muscle cells during which they express osteoblast markers. Lipids and inflammatory cytokines also increase bioapatite formation. Calcification inhibitors are matrix Gla protein and fetuin‐A. Decreased serum fetuin‐A concentration is associated with a higher mortality rate in dialysis patients. An important preventive measure for vascular calcification is the substitution of Ca‐containing by non‐Ca‐containing phosphate binders.